A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.
Ashkan Emadi, MD, PhD
Advertisement
Articles by Ashkan Emadi, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Iberdomide Combination in R/R Multiple Myeloma
2
Encorafenib/Cetuximab Plus FOLFIRI Improves PFS in BRAF V600E-Mutant mCRC
3
Onvansertib Triplet Improves Efficacy in First-Line RAS-Mutated mCRC
4
FDA OKs Once-Monthly Subcutaneous Amivantamab Dose in EGFR+ NSCLC
5